Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, SMITH TODD N, holds the title of President and CEO at Latigo Biotherapeutics, Inc..
On 2026-11-15, the insider transacted 2,207,516 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
SMITH TODD N (President and CEO) was granted $0 of $LTGO
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.